Controlled release metformin formulations
AssigneeAndrx Corporation
InventorsChih-Ming Chen, Xiu Xiu Cheng, Steve Jan, Joseph Chou
Life of this patent
Estimating the term…
Abstract
Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.
Claims29
A sustained release pharmaceutical formulation comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof, wherein said formulation provides therapeutic plasma levels of said antihyperglycemic drug to a human patient over a 24 hour period after administration to said patient.
A sustained release pharmaceutical formulation comprising a dose of metformin or a pharmaceutically acceptable salt thereof suitable for once daily dosing, said formulation providing a Tmax of the metformin which occurs at a time from about 8 hours to about 12 hours after administration to a human patient.
A sustained release pharmaceutical formulation comprising metformin or a pharmaceutically acceptable salt thereof, said formulation suitable for once daily dosing and providing a peak of a mean plasma concentration/time curve of metformin at a time from about 4 hours to about 10 hours after administration.
A sustained release pharmaceutical formulation comprising a dose of metformin or a pharmaceutically acceptable salt thereof suitable for once daily dosing, said formulation when administered with or after a meal to a human patient, providing a Cmax of metformin from about 52.8% to about 75.1% of the Cmax provided by an equivalent dose of metformin in an immediate release reference formulation.
A sustained release pharmaceutical formulation comprising a dose of metformin or a pharmaceutically acceptable salt thereof suitable for once daily dosing, said formulation when administered with or after a meal to a human patient, providing a Tmax of metformin from about 182% to about 200% of the Tmax provided by an equivalent dose of metformin in an immediate release reference formulation.
A sustained release pharmaceutical formulation comprising a dose of metformin or a pharmaceutically acceptable salt thereof suitable for once daily dosing, said formulation when administered in the fasted state to a human patient, providing a Tmax of metformin from about 173% to about 215% of the Tmax provided by an equivalent dose of metformin in an immediate release reference formulation.
A sustained release pharmaceutical formulation comprising a dose of metformin or a pharmaceutically acceptable salt thereof suitable for once daily dosing, said formulation upon administration to a human patient, providing a width at 50% of the height of a mean plasma concentration/time curve from about 6 hours to about 12 hours.
A sustained release pharmaceutical formulation comprising a dose of metformin or a pharmaceutically acceptable salt thereof suitable for once daily dosing, wherein a single administration of said formulation provides a lower mean fluctuation index in the plasma than a single administration of a substantially equal dose of an immediate release composition of metformin.
A sustained release pharmaceutical formulation comprising a dose of metformin or a pharmaceutically acceptable salt thereof that exhibits the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) and at 37° C.:
- after 2 hours 0-25% of the metformin or salt thereof is released;
- after 4 hours 10-45% of the metformin or salt thereof is released;
- after 8 hours 30-90% of the metformin or salt thereof is released;
- after 12 hours not less than 50% of the metformin or salt thereof is released;
- after 16 hours not less than 60% of the metformin or salt thereof is released;
- and after 20 hours not less than 70% of the metformin or salt thereof is released.
A sustained release pharmaceutical formulation comprising a dose of metformin or a pharmaceutically acceptable salt thereof that exhibits the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) and at 37° C.:
- after 2 hours 0-15% of the metformin or salt thereof is released;
- after 4 hours 20-40% of the metformin or salt thereof is released;
- after 8 hours 45-90% of the metformin or salt thereof is released;
- after 12 hours not less than 60% of the metformin or salt thereof is released;
- after 16 hours not less than 70% of the metformin or salt thereof is released;
- and after 20 hours not less than 80% of the metformin or salt thereof is released.
Dependencies are inferred from the claim text.